This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qin, Y. Articles by Ding, J. Search for Related Content PubMed PubMed Citation Articles by Qin, Y. Articles by Ding, J.

Research Articles: Therapeutics, Targets, and Development

Gambogic acid inhibits the catalytic activity of human topoisomerase II by binding to its ATPase domain

Divisions of ¹ Antitumor Pharmacology and ² Phytochemistry, and ³ Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, P.R. China

Requests for reprints: Jian Ding, Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, P.R. China. Fax: 86-21-50806722. E-mail: jding{at}mail.shcnc.ac.cn

Abstract

This study is intended to characterize the cellular target of gambogic acid (GA), a natural product isolated from the gamboge resin of Garcinia hurburyi tree, which possesses potent in vitro and in vivo antitumor activities. The antiproliferative activity of GA was further confirmed here in a panel of human tumor cells and multidrug-resistant cells. We found that GA significantly inhibited the catalytic activity of topoisomerase (Topo) II and, to a comparatively less extent, of Topo I, without trapping and stabilizing covalent topoisomerase-DNA cleavage complexes. Down-regulation of Topo II but not Topo I and Topo IIß, reduced GA-induced apoptosis and the phosphorylation of c-Jun, and restored cell proliferation upon GA treatment. Moreover, GA antagonized etoposide-induced DNA damage and abrogated the antiproliferative activity of etoposide, whereas it did not affect camptothecin-induced DNA damage. By dissecting the actions of GA on the individual steps of Topo II catalytic cycle, we found that GA inhibited DNA cleavage and ATP hydrolysis. Moreover, GA directly bound to the ATPase domain of Topo II, and may share common binding sites with ATP. The results reported here show that GA exerts its antiproliferative effect by inhibiting the catalytic activity Topo II. They also indicate that GA inhibits Topo II-mediated DNA cleavage and modulate the activity of Topo II poisons, which provide rationale for further clinical evaluation of GA. [Mol Cancer Ther 2007;6(9):2429–40]

Grant support: Knowledge Innovation Program of the Chinese Academy of Sciences (KSX1-SW-11-6).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

⁴ Y. Qin and J. Ding, unpublished data.

Received 3/ 2/07; revised 5/16/07; accepted 7/25/07.

This article has been cited by other articles:

				H. Gu, X. Wang, S. Rao, J. Wang, J. Zhao, F. L. Ren, R. Mu, Y. Yang, Q. Qi, W. Liu, et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells Mol. Cancer Ther., October 1, 2008; 7(10): 3298 - 3305. [Abstract] [Full Text] [PDF]

				D. Zhai, C. Jin, C.-w. Shiau, S. Kitada, A. C. Satterthwait, and J. C. Reed Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins Mol. Cancer Ther., June 1, 2008; 7(6): 1639 - 1646. [Abstract] [Full Text] [PDF]